<?xml version='1.0' encoding='utf-8'?>
<document id="25350082"><sentence text="In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP."><entity charOffset="66-79" id="DDI-PubMed.25350082.s1.e0" text="tofogliflozin" /></sentence><sentence text="Abstract 1" /><sentence text=" The metabolism and drug-drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, were evaluated by in vitro studies using human liver microsomes, human hepatocytes, and recombinant human CYPs"><entity charOffset="56-69" id="DDI-PubMed.25350082.s3.e0" text="tofogliflozin" /></sentence><sentence text=" 2" /><sentence text=" The main metabolite of tofogliflozin was the carboxylated derivative (M1) in human hepatocytes, which was the same as in vivo"><entity charOffset="24-37" id="DDI-PubMed.25350082.s5.e0" text="tofogliflozin" /></sentence><sentence text=" The metabolic pathway of tofogliflozin to M1 was considered to be as follows: first, tofogliflozin was catalyzed to the primary hydroxylated derivative (M4) by CYP2C18, CYP4A11 and CYP4F3B, then M4 was oxidized to M1"><entity charOffset="26-39" id="DDI-PubMed.25350082.s6.e0" text="tofogliflozin" /><entity charOffset="86-99" id="DDI-PubMed.25350082.s6.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.25350082.s6.e0" e2="DDI-PubMed.25350082.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25350082.s6.e0" e2="DDI-PubMed.25350082.s6.e1" /></sentence><sentence text=" 3" /><sentence text=" Tofogliflozin had no induction potential on CYP1A2 and CYP3A4"><entity charOffset="1-14" id="DDI-PubMed.25350082.s8.e0" text="Tofogliflozin" /></sentence><sentence text=" Neither tofogliflozin nor M1 had inhibition potential on CYPs, with the exception of a weak CYP2C19 inhibition by M1" /><sentence text=" 4" /><sentence text=" Not only are multiple metabolic enzymes involved in the tofogliflozin metabolism, but the drug is also excreted into urine after oral administration, indicating that tofogliflozin is eliminated through multiple pathways"><entity charOffset="57-70" id="DDI-PubMed.25350082.s11.e0" text="tofogliflozin" /><entity charOffset="167-180" id="DDI-PubMed.25350082.s11.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.25350082.s11.e0" e2="DDI-PubMed.25350082.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25350082.s11.e0" e2="DDI-PubMed.25350082.s11.e1" /></sentence><sentence text=" Thus, the exposure of tofogliflozin would not be significantly altered by DDI caused by any co-administered drugs"><entity charOffset="23-36" id="DDI-PubMed.25350082.s12.e0" text="tofogliflozin" /></sentence><sentence text=" Also, tofogliflozin seems not to cause significant DDI of co-administered drugs because tofogliflozin has no CYP induction or inhibition potency, and the main metabolite M1 has no clinically relevant CYP inhibition potency"><entity charOffset="89-102" id="DDI-PubMed.25350082.s13.e0" text="tofogliflozin" /></sentence><sentence text=" " /></document>